- Home
- Results news
- Paras Healthcare
- Q2 FY27 results
Paras Healthcare Q2 FY27 results: net profit ₹40.35 crore
Paras Healthcare Limited reported consolidated revenue of ₹510.89 crore and net profit of ₹40.35 crore for Q2 FY27, with an EBITDA margin of 23.5%. The company also reported first-half revenue of ₹981.17 crore and net profit of ₹90.03 crore.
Key points
- Consolidated Q2 FY27 revenue was ₹510.89 crore, while EBITDA was ₹120.18 crore and the EBITDA margin was 23.5%.
- Consolidated Q2 FY27 profit before tax was ₹54.22 crore and net profit was ₹40.35 crore, with basic EPS of ₹4.00.
- Standalone Q2 FY27 revenue was ₹412.97 crore and profit after tax was ₹39.18 crore.
- For H1 FY27, consolidated revenue was ₹981.17 crore, profit before tax was ₹102.34 crore and net profit was ₹90.03 crore.
- At 30 September 2026, total assets were ₹2,315.77 crore, total equity was ₹486.15 crore, borrowings were ₹979.01 crore and cash was ₹44.55 crore.
How did Paras Healthcare perform in Q2 FY27?
Paras Healthcare reported consolidated revenue from operations of ₹510.89 crore for Q2 FY27. Other income was ₹6.45 crore and total expenses were ₹463.13 crore. EBITDA was ₹120.18 crore, giving an EBITDA margin of 23.5%. Profit before tax was ₹54.22 crore, while the company reported a net profit of ₹40.35 crore and basic EPS of ₹4.00. There was no exceptional item.
For H1 FY27, consolidated revenue was ₹981.17 crore, total income was ₹996.09 crore, profit before tax was ₹102.34 crore and net profit was ₹90.03 crore, with basic EPS of ₹8.92. Standalone Q2 FY27 revenue was ₹412.97 crore and profit after tax was ₹39.18 crore. The board approved the unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026, and Walker Chandiok & Co LLP issued unmodified limited review reports.
| ₹ crore | Q2 FY27 |
|---|---|
| Revenue from operations | 510.89 |
| Other income | 6.45 |
| Total expenses | 463.13 |
| EBITDA | 120.18 |
| EBITDA margin | 23.5% |
| Profit before tax | 54.22 |
| Tax | 13.87 |
| Net profit | 40.35 |
| EPS (₹) | 4.00 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, Paras Healthcare reported total assets of ₹2,315.77 crore and total equity of ₹486.15 crore. Borrowings were ₹979.01 crore and cash and cash equivalents were ₹44.55 crore. Inventories stood at ₹39.44 crore, trade receivables at ₹517.90 crore and trade payables at ₹247.23 crore. The provided balance-sheet data does not include a previous balance-sheet date for comparison.
For H1 FY27, operating cash flow was ₹68.17 crore, investing cash flow was negative ₹133.87 crore and financing cash flow was ₹63.05 crore. Capital expenditure was ₹90.17 crore. The filing data does not provide the corresponding H1 FY26 cash-flow figures for comparison.
| ₹ crore | As of 30 September 2026 |
|---|---|
| Total assets | 2,316 |
| Total equity | 486.15 |
| Borrowings | 979.01 |
| Cash and equivalents | 44.55 |
| Inventories | 39.44 |
| Trade receivables | 517.90 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 |
|---|---|
| Cash from operations | 68.17 |
| Cash from investing | −133.87 |
| Cash from financing | 63.05 |
| Capital expenditure | 90.17 |
Source: Company's results filing (XBRL).
What else did the company announce?
On 5 November 2026, the board approved the continuation of Mr. Kabir Kishin Thakur as a non-executive non-independent director under Regulation 17(1D) of the SEBI Listing Regulations, subject to shareholder approval. The company stated that he was not debarred from holding office as a director by any SEBI order or other authority. The same-day filing did not announce a dividend or a fund raise.
On 2 November 2026, Paras Healthcare informed the exchanges that the board would meet on 5 November 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The company also said the trading window remained closed for designated persons and their immediate relatives until 48 hours after the results declaration.
Quick answers
What was Paras Healthcare's revenue in Q2 FY27?
Revenue from operations was ₹510.89 crore (consolidated).
Did Paras Healthcare make a profit in Q2 FY27?
Yes. Net profit was ₹40.35 crore.
What was Paras Healthcare's EPS in Q2 FY27?
Basic earnings per share were ₹4.00.
When did Paras Healthcare announce its Q2 FY27 results?
On 5 November 2026, in a filing to the NSE.
Sources
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.